Rani Therapeutics (Nasdaq:RANI) shares dipped on fourth-quarter results that just managed to beat the consensus EPS forecast. Shares of RANI fell 4.2% at $5.70 apiece in midday trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — dipped 0.6%. The San Jose, California-based robotic pill maker posted […]
Rani Therapeutics
Rani Therapeutics launches RT-111 development program
Robotic pill company Rani Therapeutics (Nasdaq:RANI) has begun developing RT-111, a RaniPill GO capsule containing a biosimilar of Johnson & Johnson’s (NYSE:JNJ) Stelara (ustekinumab). The company anticipates that RT-111 could potentially treat psoriatic arthritis, ulcerative colitis, Crohn’s disease and psoriasis. The FDA first approved Stelara in 2009 for psoriasis. Stelara is available in intravenous and […]
Rani Therapeutics’ stock jumps 69% after IPO
Rani Therapeutics Holdings (NSDQ:RANI) recently announced the closing of its initial public offering (IPO) of 7,666,667 shares of its Class A common stock. The stock began trading at $11, trailing the company’s expected range of $14 to $16. Today, the stock closed at $18.61, representing a 69.18% increase. RANI shares were trading even higher on […]
